Closely-held PharmaJet announced that its Tropis Intradermal (ID) Needle-free System was selected by WHO for use in a house-to-house immunization campaign targeting more than 170,000 children, age four to 59 months, in four districts in Banadir, Somalia.
The campaign, a collaboration of the African Field Epidemiology Network, WHO, UNICEF, BMGF, GAVI, and CDC, aims to reduce the immunity gap against type-2 poliovirus and will be conducted in two rounds. More than a quarter million of PharmaJet’s needle-free intradermal syringes have been provided to support this initiative.
In a statement, Paul, LaBarre, vice-president of global business development at PharmaJet, said, “In Somalia, we are eager to build on previous house-to-house campaign experience that demonstrates how needle-free enables vaccination teams to move quickly and achieve high coverage without the burden of sharps waste management and with reduced vaccine volume and cold chain logistics.”
PharmaJet Precision Delivery Systems can improve increased vaccine effectiveness and are safe, fast, and easy-to-use, allowing a preferred patient caregiver experience, he added.
